ReviewFrontiers in medicine2021
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic reviews of convalescent plasma in COVID-19 continue to be poorly conducted and reported: a systematic review.Journal of clinical epidemiology · 2022Pooled it
- Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.JAMA network open · 2022Pooled it
- The effect of early COVID-19 treatment with convalescent plasma on antibody responses to SARS-CoV-2.Microbiology spectrum · 2025Trial
- Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.European journal of internal medicine · 2022Trial
- A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.Nature communications · 2022Trial
- Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center.PloS one · 2022Trial
- Intelligent Patient Management in Viral Diseases: An Integrated Regression Model and Multi-Criteria Decision-Making Approach to Convalescent Plasma Transfusion.Healthcare (Basel, Switzerland) · 2025Article
- Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.Current pharmaceutical design · 2025Review
- COVID-19 clinical presentation, management, and epidemiology: a concise compendium.Frontiers in public health · 2025Review
- Development of a nomogram for high antibody titre of COVID-19 convalescent plasma.Epidemiology and infection · 2024Article
- Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Use of convalescent plasma in COVID-19 treatment: is clinical severity more important than the intervention?Einstein (Sao Paulo, Brazil) · 2024Article
- Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study.Life science alliance · 2024Article
- Coinfections and Superinfections Associated with COVID-19 in Colombia: A Narrative Review.Medicina (Kaunas, Lithuania) · 2023Review
- Exercise and Experiments of Nature.Comprehensive Physiology · 2023Article
- Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.Viruses · 2023Article
- Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.Journal of Taibah University Medical Sciences · 2023Review
- Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from SARS-CoV-2 in a US-like population.Transfusion · 2023Article
- Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.Journal of blood medicine · 2023Review
- What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral load evolution and immune response.Frontiers in nephrology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Convalescent plasma has been used worldwide to treat patients hospitalized with coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global usage, uncertainty remains regarding plasma efficacy, as randomized controlled trials (RCTs) have provided divergent evidence regarding the survival benefit of convalescent plasma. Here, we argue that during a global health emergency, the mosaic of evidence originating from multiple levels of the epistemic hierarchy should inform contemporary policy and healthcare decisions. Indeed, worldwide matched-control studies have generally found convalescent plasma to improve COVID-19 patient survival, and RCTs have demonstrated a survival benefit when transfused early in the disease course but limited or no benefit later in the disease course when patients required greater supportive therapies. RCTs have also revealed that convalescent plasma transfusion contributes to improved symptomatology and viral clearance. To further investigate the effect of convalescent plasma on patient mortality, we performed a meta-analytical approach to pool daily survival data from all controlled studies that reported Kaplan-Meier survival plots. Qualitative inspection of all available Kaplan-Meier survival data and an aggregate Kaplan-Meier survival plot revealed a directionally consistent pattern among studies arising from multiple levels of the epistemic hierarchy, whereby convalescent plasma transfusion was generally associated with greater patient survival. Given that convalescent plasma has a similar safety profile as standard plasma, convalescent plasma should be implemented within weeks of the onset of future infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.